Obstructive sleep apnea increases cardiovascular risk through multiple interacting biological and mechanical pathways. Virend K. Somers at the Mayo Clinic and colleagues working for the American Heart Association described how recurrent airway collapse during sleep produces physiological stresses that promote hypertension, atherosclerosis, arrhythmias, and heart failure. These pathways explain the epidemiologic associations between sleep-disordered breathing and adverse cardiac events.
Intermittent hypoxia and sympathetic activation
Recurrent apneas produce intermittent hypoxia, abrupt falls in blood oxygen that trigger chemoreflexes and bursts of sympathetic activation. Atul Malhotra at the University of California San Diego has emphasized how these repeated sympathetic surges raise nighttime and daytime blood pressure and increase heart rate variability in a harmful direction. Over time, persistent sympathetic overactivity drives sustained hypertension and vascular remodeling, elevating long-term cardiovascular risk.
Inflammation, oxidative stress, and endothelial dysfunction
Intermittent hypoxia and fragmented sleep provoke systemic inflammation and oxidative stress, damaging the endothelium that lines blood vessels. Evidence summarized by Virend K. Somers and the American Heart Association links increased circulating inflammatory markers and impaired endothelial function to accelerated atherosclerosis in people with sleep apnea. These molecular changes make plaques more likely to form and to rupture, increasing the risk of myocardial infarction and stroke.
Mechanical load, arrhythmia triggers, and metabolic effects
Large negative intrathoracic pressure swings during obstructed inspiration increase cardiac wall stress and venous return, imposing acute mechanical load on the heart and promoting left ventricular hypertrophy and heart failure in susceptible individuals. These pressure swings and intermittent hypoxia also predispose to electrical instability, contributing to atrial fibrillation and other arrhythmias. Sleep apnea is associated with adverse metabolic changes including insulin resistance and dyslipidemia, which further compound cardiovascular risk.
Relevance extends beyond biology. Obesity, common in many cultures and regions, markedly increases sleep apnea prevalence and amplifies cardiovascular consequences. Access to diagnosis and continuous positive airway pressure therapy varies by territory and socioeconomic status, shaping outcomes across populations. Clinical guidance from the American Heart Association and expert groups led by Virend K. Somers recommends recognizing sleep apnea as a modifiable cardiovascular risk factor, because treating airway obstruction and associated comorbidities can reduce physiological stressors that drive heart disease. Effect sizes for treatment vary by condition and population, underscoring the need for individualized care and equitable access to screening and therapy.